Synonyms
|
|
Allscripts (AEHR) Order Name
|
N-Telopeptide Cross-link (NTx) Urine
|
Sunrise Clinical Manager (SCM) Order Name
|
N-Telopeptides w/Creatinine
|
Clinical Info
|
Evaluation of osteoporosis and assessment of antiresorptive therapy
|
Specimen Type
|
Urine
|
Container
|
Urine-Yellow Top
|
Collection Instructions
|
Container/Tube: Sterile leak-proof container
Specimen: 20 mL from a second-morning urine collection. Discard first-morning urine. No preservative.(1 mL min)
Transport Temperature: Refrigerated
Stability: 14 Days Room Temperature, Refrigerated, or Frozen
Collection Collect a second void of the morning or an aliquot of a 24-hour urine (no preservative). When monitoring therapy, baseline samples should be collected prior to initiation of therapy. Subsequent specimens should be collected at the same time of day as baseline specime
|
Transport Instructions
|
Refrigerated
|
Specimen Stability
|
14 Days Room Temperature, Refrigerated, or Frozen
Collection Collect a second void of the morning or an aliquot of a 24-hour urine (no preservative). When monitoring therapy, baseline samples should be collected prior to initiation of therapy. Subseq
|
Methodology
|
Ortho Vitros Enhanced Chemiluminescence System
|
Days Performed
|
|
Performing Laboratory
|
LabCorp
|
CPT
|
82523 - collagen crosslinks
82570 - creatinine
TAT: 3-5 Days
Loinc: 14115-0
|
PDM
|
5900486
|
Result Interpretation
Pediatric: see table.1
• Adults:
− Male: 0−62 nM BCE/mmol creatinine
− Female: 20 to 49 years 0−64 nM BCE/mmol
creatinine; >49 years 0−89 nM BCE/mmol creatinine
Tanner Stage
|
I
|
Male
(nM BCE/mmol creatinine)
|
55−508
|
Female
(nM BCE/mmol creatinine)
|
6−662
|
II
|
Male
(nM BCE/mmol creatinine)
|
21−423
|
Female
(nM BCE/mmol creatinine)
|
193−514
|
III
|
Male
(nM BCE/mmol creatinine)
|
27−462
|
Female
(nM BCE/mmol creatinine)
|
13−632
|
IV
|
Male
(nM BCE/mmol creatinine)
|
<609
|
Female
(nM BCE/mmol creatinine)
|
<389
|
V
|
Male
(nM BCE/mmol creatinine)
|
<240
|
Female
(nM BCE/mmol creatinine)
|
<132
|
Tanner Stage
|
Male
(nM BCE/mmol creatinine)
|
Female
(nM BCE/mmol creatinine)
|
I
|
55−508
|
6−662
|
II
|
21−423
|
193−514
|
III
|
27−462
|
13−632
|
IV
|
<609
|
<389
|
V
|
<240
|
<132
|
|
Forms
|
|
